Nevertheless, the prevalence of NPM1, FLT3-ITD and CEBPA mutations in our patients were quite similar to those in Taiwanese and Chinese patients with de novo AML [5, 6, 28]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.